JosephHarryAntinMD

Hematology • Boston, MA

Hematologic Oncology

Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Antin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Antin's full profile

Already have an account?

Office
44 Binney St
# Dana-Far
Boston, MA 02115
Phone+1 617-632-3667

Fax+1 617-632-5175

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1981 - 1983
Brigham and Women's HospitalResidency, Internal Medicine, 1978 - 1981
Weill Cornell MedicineClass of 1978

Certifications & Licensure

MA State Medical License 1986 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Boston Magazine Castle Connolly, 2008-2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Boston Herald Castle Connolly, 2005
Elected Member The American Society for Clinical Investigation, 1997
Elected member American Assocation of Physicians
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Blood and Marrow Transplant Clinical Research Network Start of enrollment: 2001 Sep 01
Completed
Not Applicable
Phase I Study of Sequential Cord Blood Transplants Start of enrollment: 2003 May 01
Completed
Phase 1
Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
Completed
Phase 1, Phase 2
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Start of enrollment: 2006 Sep 01
Terminated
Phase 2
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) Start of enrollment: 2010 Oct 01
Completed
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001) Start of enrollment: 2022 Jul 12
ACTIVE_NOT_RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
Mark C Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K Waller
Blood Advances. 2025-03-11
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gra...
Cindy Lynn Hickey, Mei-Jie Zhang, Mariam Allbee-Johnson, Rizwan Romee, Navneet S Majhail
Transplantation and Cellular Therapy. 2025-03-01
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation: A Randomized Clinical Trial.
Gregory A Abel, Haesook T Kim, Ira Zackon, Edwin T Alyea, Alexandra S Bailey
JAMA Oncology. 2025-03-01

Journal Articles

Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host Disease
Joseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood

Abstracts/Posters

Improved Outcomes with Cyclophosphamide/Total Body Irradiation 14 Gy Compared to Cyclophosphamide/Total Body Irradiation 12 Gy in Patients with Acute Lymphoblastic Leu...
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Anti-CD6 Monoclonal Antibody Itolizumab Efficiently Inhibits T Cell Proliferation after in Vitro TCR Stimulation in the Setting of Acute Graft Versus Host Disease
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase II Trial to Compare Allogeneic Transplant Vs. Standard of Care for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Pr...
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Development of HHV-6-Specific Immunity after Cord Blood Transplantation in Adults Depends on Reconstitution of Thymopoiesis and Regeneration of CD4+ T Cells
Joseph H. Antin, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/8/2019
Join now to see all

Lectures

Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B-Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Dana-Farber Researchers to Showcase Pivotal Transplant and Cellular Therapy Findings at 2025 Tandem MeetingsFebruary 12th, 2025
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem MeetingsFebruary 12th, 2025
ASBMT NewsOctober 13th, 2018
Join now to see all

Grant Support

A Randomized Trial Of Tac/Mtx/Bortezomib VS Tac/Mtxplacebo In Allogeneic HSCTNational Heart, Lung, And Blood Institute2011
Novel Approaches To Graft-Versus-Host Disease PreventionNational Cancer Institute2009–2011
Mechanisms Of GVHDNational Cancer Institute2009–2011
Administrative CoreNational Cancer Institute2009–2011
Random Trial Of CD8 T-Cell Depletion In PBSC TransplantationNational Heart, Lung, And Blood Institute2006–2010
Novel Approaches To Ghvd PreventionNational Heart, Lung, And Blood Institute2007
Mechanisms Of GVHDNational Heart, Lung, And Blood Institute2003–2007
Randomized Trial Of CD8 T-Cell Depletion In PBSC Transp*National Heart, Lung, And Blood Institute2001–2005
Use Of Unrelated Donors For Bone Marrow TransplantationNational Center For Research Resources1997–1999
Phlebotomy For Research Studies After Marrow TransplantationNational Center For Research Resources1997–1999
Core--Clinical Bone Marrow Transplant ProgramNational Cancer Institute1997
Novel Therapy For Chronic Myelogenous LeukemiaNational Cancer Institute1993–1996